Experimental drug 'nothing short of miraculous' for father of 4 with super-rare brain tumor This is the drug that we recently gave a million dollar grant to help support and speed up it's development! The mutation (H3K27 M) is very common in DIPG, and common in midline and thalmic malignant gliomas, more so in younger GBM patients. This experimental drug is in clinical trials. Check your pathology report to see if you have this mutation. If you do, contact us and we can help you find a trial. (It is so common in DIPG that no biopsy is needed to get into the trials for that tumor type - it is assumed they all have this)
This shows that Optune has finally hit the mainstream.55 presentations at the major European brain tumor conference.Many of these are looking at ways to improve the outcomes, including new types of arrays, new placement of arrays for tumors lower in the skill and for pediatric patients.
Bevacizumab: Is the lower the better for glioblastoma patients in progression? This one is hard to interpret. The authors say that a low dose is just as effective as the standard dose of Avastin, but with less side effects (and less cost). They should have included the control gorup of patients who do not use Avastin. But it is something to think about.
Inhibition of Radiation and Temozolomide-Induced Invadopodia Activity in Glioma Cells Using FDA-Approved Drugs. I love this type of research. Invadopoia are small projections from the edges of tumnor cells that help allow them to move. Without the ability to move, the tumor is much less dangerous and more sensitive to normal treatments. This is a highly underappreciated target and they found 2 existing drugs which may target this. Of course, it is just theory now and needs to be tested but it is a promising approach!
